APA (7th ed.) Citation

L, M., G, L., G, P., E, G., R, T., F, C., . . . A, S. (2022). Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study. International immunopharmacology, 107, 108709. https://doi.org/10.1016/j.intimp.2022.108709

Chicago Style (17th ed.) Citation

L, Masotti, et al. "Predictors of Poor Outcome in Tocilizumab Treated Patients with Sars-CoV-2 Related Severe Respiratory Failure: A Multicentre Real World Study." International Immunopharmacology 107 (2022): 108709. https://doi.org/10.1016/j.intimp.2022.108709.

MLA (9th ed.) Citation

L, Masotti, et al. "Predictors of Poor Outcome in Tocilizumab Treated Patients with Sars-CoV-2 Related Severe Respiratory Failure: A Multicentre Real World Study." International Immunopharmacology, vol. 107, 2022, p. 108709, https://doi.org/10.1016/j.intimp.2022.108709.